Status: Recruiting
Study of HLD-0915 in Patients With Metastatic Prostate Cancer
Assessment of the safety and efficacy of HLD-0915 in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Participants needed: 190
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: Halda Therapeutics OpCo, Inc.Updated: Jun 26, 2026Locations: 12
Eligibility criteria
Not listed